<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01524211</url>
  </required_header>
  <id_info>
    <org_study_id>IDE G110081</org_study_id>
    <nct_id>NCT01524211</nct_id>
  </id_info>
  <brief_title>Evaluation of Branch Endografts in the Treatment of Aortic Aneurysms</brief_title>
  <official_title>Evaluation of Branch Endografts in the Treatment of Aortic Aneurysms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lee, W. Anthony, M.D. FACS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>William Cook Australia</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lee, W. Anthony, M.D. FACS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect information on the Cook Zenith t-Branch endovascular
      stent-graft system for the treatment of aortic aneurysms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Update as of 10/31/2017;84 subjects successfully have been implanted with the Zenith
      t-Branch Device to date and recruitment is ongoing.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Early Mortality</measure>
    <time_frame>30 days post implant of the branch endografts</time_frame>
    <description>The primary aim of this study is to determine the rate of early mortality after branch endograft treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of Neurologic Complications/Late Branch Vessel Patency</measure>
    <time_frame>Day 0-Day 30 (Early) Day 31-1825 (Late)</time_frame>
    <description>The secondary aims of this study are to determine the rates of neurologic complications and late branch vessel patency after branch endograft treatment, and the fractional/proportional/percent applicability/eligibility of the (standard, off-the-shelf) Zenith® t-Branch in all patients who present with thoracoabdominal aortic aneurysms</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Thoracoabdominal Aortic Aneurysm</condition>
  <arm_group>
    <arm_group_label>Single Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects enrolled will receive endovascular treatment with the investigational Zenith t-Branch Endovascular Graft.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Zenith® t-Branch</intervention_name>
    <description>The t-Branch Endovascular Graft (Zenith® t-Branch) is a tubular graft with four branches and a covered stent at the proximal end that contains barbs for additional fixation of the device. The purpose of the branches is to allow uninterrupted blood flow to visceral vessels of the aorta. The graft is designed to be connected with celiac, superior mesenteric and two renal arteries via self-expanding covered bridging stents. Although the standard Zenith t-Branch has four branches, it is anticipated that a small number of custom-made three branch devices will be included in this study for those patients in whom one of the visceral vessels is chronically thrombosed.</description>
    <arm_group_label>Single Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        The patient must have one of the following:

          1. Degenerative, atherosclerotic thoracoabdominal, suprarenal and juxtarenal aortic
             aneurysms (fusiform or saccular):≥55mm in diameter in a male or ≥50mm in diameter in a
             female, or

          2. Thoracoabdominal aortic aneurysm with a history of growth ≥0.5 cm per year, or

          3. Penetrating ulcers: ≥20mm in depth or

          4. Chronic type B aortic dissections: ≥50mm total aortic diameter or

          5. Symptomatic pathology (aneurysm, ulcer or chronic dissection) of any size.

        Additional criteria for LP material

        • Iliofemoral access vessels &lt;8mm or with significant atherosclerotic occlusive disease
        that would require an iliac conduit as determined by the Principle Investigator

        Exclusion Criteria

        General Criteria

          1. Life-expectancy less than 12 months

          2. Refusal to receive blood products

          3. Age &lt;18 years

          4. Pregnant or breastfeeding or planning on becoming pregnant within 60 months

          5. Unwilling to comply with the follow-up schedule

          6. Inability or refusal to give informed consent by subject and/or Legally Authorized
             Representative (LAR); should one be utilized

        Medical Criteria

          1. Uncontrolled systemic infection

          2. Untreatable malignancy

          3. Uncontrollable anaphylaxis to iodinated contrast

          4. Known allergy(ies) to device materials

        Anatomic Criteria

          1. Any pathology of mycotic origin

          2. Aortic fistulous communication with non-vascular structure (e.g. esophagus, bronchial)

          3. Inability to insert the Zenith® t-Branch device through iliofemoral approach

          4. Proximal and distal neck angle less than 90 degrees relative to the long axis of the
             aneurysm

          5. Proximal landing zone length &lt;25mm to allow secure fixation and seal

          6. Proximal landing zone diameter of &lt;24mm or &gt;42mm

          7. Distal landing zone length &lt;25mm in the abdominal aorta or &lt;20mm in the iliac arteries

          8. Distal landing zone diameter of &lt;14mm or &gt;30mm in the abdominal aorta, or &lt;7mm or
             &gt;28mm in the iliac arteries
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>W. Anthony Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lynn Heart and Vascular Institute, Boca Raton Regional Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisamarie Kernicky, RN;BSN;CCRC</last_name>
    <phone>561-955-5239</phone>
    <email>lkernicky@brrh.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Boca Raton Regional Hospital (BRRH)</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisamarie Kernicky, RN;BSN;CCRC</last_name>
      <phone>561-955-5239</phone>
      <email>lkernicky@brrh.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2012</study_first_submitted>
  <study_first_submitted_qc>January 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2012</study_first_posted>
  <last_update_submitted>October 31, 2017</last_update_submitted>
  <last_update_submitted_qc>October 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic Aneurysms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Thoracic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

